3rd International Conference on Dengue and DHF Schedule-15 Sep 13-Approved.pdf

(Tentative) Scientific Program for the 3rd International Conference on Dengue/DHF 21-23 Oct 2013 [update on 15 September 2013]

Time Queen's Park 1 Queen's Park 2 Queen's Park 3 Queen's Park 4-5

08.00-09.00

Welcome Address:

Report by:

Opening remark: Dr. Samlee Plianbangchang (Regional Director of WHO/SEARO)

Opening speech: (Minister of Public Health)

10.30-11.00

12.00-13.00

13.00-13.45

14.30-17.30 Symposium 1: Global Dengue Situation 14.30-16.00 Symposium 2: Highlight from Fifty Years of Dengue

Experience and Research at Queen Sirikit National Institute of

Child Health

14.30-16.00 Symposium 3: Emerging Flavivirus and

Epidemiology of DENV

Special Symposium by DVI: Generating Evidence for Decision

Making regarding the Introduction of Dengue Vaccines

Chair: Duane Gubler (USA)

Co-chair: Kamnuan Ungchusak (THA)

Chair: Timothy Endy (USA)

Co-chair: Siraporn Sawadiworn (THA)

Chair: Pratap Singhasivanont (THA)

Co-chair: Richard G Jarman (USA)

Chair: Georges Thiry (BEL)

Co-chair: Pornthep Chanthavanich (THA)

14.30-15.00 Duane Gubler (USA)

Dengue - Global health problem and threat

14.30-15.00 Suchitra Nimmannitya (THA)

Interweaving clinical experience with research works in dengue:

Towards best achievement

14.30-14.45 (0215R01) Basu Dev Pandey (NPL)

First isolation of dengue virus from Nepal

14.30-14.50 Pornthep Chanthavanich (THA)

Burden of dengue infection in children and adults in Bang Phae

district, Ratchaburi

14.45-15.00 (0025R01) Nikos Vasilakis (USA)

The daemon in the forest-emergence of a new dengue serotype in

SouthEast Asia

14.50-15.10 (0220R01) Jacqueline Lim (KOR)

Burden of dengue infection in children and adults of Santa Cruz

comuna of Medellin, Columbia

15.00-15.20 A P Dash (WHO/SEARO)

Dengue in South East Asia

15.00-15.30 In-Kyu Yoon (USA)

Insights into host and viral factors in dengue severity

15.00-15.15 (0145R01) Robert Reiner (USA)

Estimating time-varying epidemiological parameters of dengue virus

using longitudinal serological data

15.15-15.30 (0116R01) Bernard Cazelles (FRA)

Rural origin of the propagation of dengue in SouthEast Asia

15.10-15.30 (0267R01) Vittal Mogasale (IND)

A multi-country study of the economic burden of dengue fever and

household willingness to pay for dengue vaccines

15.20-15.40 (WHO/WPRO)

Dengue in Western Pacific15.30-16.00 Anon Srikiatkhachorn (THA)

Clinical and immunologic studies in dengue at Queen Sirikit National

Institute of Child Health

15.30-15.45 (0246R01) Sowath Ly (KHM)

Epidemiology of clusters in identified dengue cases' households in

rural Cambodia, 2013 - preliminary results

15.30-15.50 Nyambat Batmunkh (MNG)

Update on the DVI activity in Brazil “Ensuring rapid introduction of

dengue vaccines through first-to-introduce countries”

15.40-16.00 Kay Tomashek (PRI)

Emerging of dengue in USA

-To be continued after coffee break-15.45-16.00 (0257R01) Alex Perkins (USA)

Impacts of dengue infection on human mobility

16.00-16.30

16.30-17.20 Symposium 1: Global Dengue Situation (Continued) 16.30-17.30 Symposium 4: Lessons Learned from Cohort

Studies

16.30-17.30 Symposium 5: Health Economic Communication &

Community Empowerment

16.30-17.30 Symposium 6: Epidemiology

Chair: Anon Srikiatkhachorn (THA)

Co-chair: Timothy Endy (USA)

Chair: Amara Soonthorndhada (THA)

Co-chair: Chiu-Wan Ng (MYS)

Chair: Wichai Satimai (THA)

Co-chair: Sopon Iamsiritaworn (THA)

16.30-16.50 Harold Margolis (USA)

Dengue in Africa

16.30-16.50 Timothy Endy (USA)

Lessons learned from prospective cohort studies on dengue

transmission and disease severity

16.30-16.50 Chiu-Wan Ng (MYS)

Would economic burden of dengue infections in Malaysia do?

16.30-16.50 Karen Campbell (USA)

Using a dengue transmission model to inform prevention policy and

decision making

16.50-17.20 Raman Velayudhan (WHO/GENEVA)

Global strategy for dengue prevention and control


What we have learned from dengue cluster studies

16.50-17.10 Veerle Vanlerberghe (BEL)

Household uptake and use of intervention tools influencing the scale

of effect of dengue vector control

16.50-17.10 Rome Buathong (THA)

Seroprevalence and risk factors of dengue infection in Rayong,

Thailand, 2010

17.10-17.30 Chukiat Sirivichayakul (THA)

Clinical manifestration of dengue; A cohort study

17.10-17.25 (0229R01) Packierisamy Raviwharmman (MYS)

Comparing cost of dengue vector control services between different

delivery agencies in Malaysia

17.10-17.30 Hasitha Tissera (LKA)

Epidemiology of dengue in Sri Lanka: Evolution into a major public

health and clinical entity

19.00-21.30

Day 1: 21 October 2013

09.00-10.30

Break

11.00-12.00

Welcome Dinner

Break

Luncheon Symposium 1

Poster Presentation

13.45-14.30

Chair: Prof. Emeritus Prasert Thongcharoen (Chair of Scientific Organizing Committee)

16.30-17.30

14.30-16.00

REGISTRATION

OPENING CEREMONY

SPECIAL LECTURE

Scott B Halstead (USA) The basic science behind successful dengue vaccine

13.45-14.30 Prof. Natth Bhamarapravati Memorial Lecture

13.45-14.10 Jean Lang (FRA) Thailand : Three decades at the forefront of dengue vaccine development

14.10-14.30 Sutee Yoksan (THA) Prof. Natth's initiation and achievement on dengue vaccine development

Page 1 of 5



State-of-the-Art Lecture 1: 08.30-09.30 Symposium 7: Laboratory Diagnosis 08.30-09.30 Symposium 8: Activation and Evasion of Innate

Immunity by Dengue Virus

08.30-09.30 Symposium 9: Vaccine I

Chair: Ichiro Kurane (JPN)

Co-chair: Ananda Nisalak (THA)

Chair: Kenneth Rock (USA)

Co-chair: Anon Srikiatkhachorn (THA)

Chair: Sutee Yoksan (THA)

Co-chair: In-Kyu Yoon (USA)

08.30-09.15 Donald Roberts (USA)

The continuing need for public health insecticides in dengue control?

08.30-09.00 Ichiro Kurane (JPN)

An overview on dengue diagnosis

08.30-08.50 Douglas Golenbock (USA)

Innate immunity and infectious diseases

08.30-08.45 (0114R01) Suh-Chin Wu (TWN)

Reduced mouse neurovirulence and enhanced heparin binding for

dengue type 4 viruses containing the adaptive mutations(s) form

MRC-5 cells

08.50-09.10 Chia-Yi Yu (TWN)

Activation and evasion of type I interferon response in dengue virus

infection

08.45-09.00 (0142R01) Tamaki Okabayashi (JPN)

The evolution of dengue virus serotype 2 in Thailand: a possible

explanation of a 75% solution of dengue vaccine development

09.00-09.30 Stefan Fernandez (USA)

Experience on diagnostic assays and value of rapid test for dengue

diagnosis

09.10-09.30 Panisadee Avirutnan (THA)

Complement response in dengue - a double edged sword

09.00-09.15 (0252R01) Martha Erika Navarro Sanchez (USA)

Optimization of dengue E protein-based immunogens

09.15- 10.30 Symposium 10: Innovative Vector Control and

Approaches

09.30-10.30 Symposium 11: Laboratory Diagnosis 09.30-10.30 Symposium 12: The Roles of Adaptive Immunity in

Protection and Disease

09.30-10.30 Symposium 13: Vaccine II

Chair: Tom Scott (USA)

Co-chair: Suvit Limawongpranee (THA)

Chair: Umesh Chaturvedi (IND)

Co-chair: Uraiwan Kositanont (THA)

Chair: Prida Malasit (THA)

Co-chair: Panisadee Avirutnan (THA)

Chair: Nopporn Sittisombut (THA)

Co-chair: Chukiat Sirivichayakul (THA)

09.15-09.40 Nicole Achee (USA)

Spatial repellent products for dengue control

09.30-09.45 (0310R01) Elizabeth Hunsperger (PRI)

Evaluation of commercially available dengue diagnostic tests for

detection of NS1 antigen and anti-DENV IgM: a WHO/TDR multi-

center study

09.30-09.50 Juthatip Mongkolsapaya (THA)

The human antibody response to dengue virus

09.30-09.45 (0186R01) Navin Khanna (IND)

Dengue virus envelope-based VLP vaccine

09.40-10.10 Vincent Corbel (FRA)

Molecular basis of insecticide resistance in Aedes aegypti and impact

on space spray efficacy09.45-10.00 (0154R01) Anne-Claire Andries (KHM)

Use of urine and saliva for the diagnosis of dengue infection09.50-10.10 Alan Rothman (USA)

Prospective studies of human T cell responses to dengue-what are

the implications for vaccines and therapeutics?

09.45-10.00 (0347R01) Chonlatip Pipattanaboon (THA)

Epitope mapping of human monoclonal antibodies generated from

dengue patients for ideal vaccine development

10.10-10.30 Micheal J Bangs (USA)

Past, current and innovative approaches to a persistent challenge-

dengue vector control

10.00-10.15 (0155R01) Kebaneilwe Lebani (AUS)

Development of a serotyping NS1 captuer assay for diagnosis of

acute, primary dengue virus infections

10.10-10.30 Izabela Rodenhuis-Zybert (NLD)

New insights in antibody-dependent enhancement of dengue virus

infection

10.00-10.15 (0363R01) Robert Beatty (USA)

Dengue virus NS1 as a vaccine to prevent NS1-induced toxicity

10.15-10.30 (0218R01) Ada Alves (BRA)

Mapping the protective immune response induced by a DNA vaccine

against dengue 2 based on the NS1 protein

10.30-11.00

11.00-12.00 Symposium 14: Vector Biology and Behavior State-of-the-Art Lecture 2: 11.00-12.00 Symposium 15: Adaptive and Innate Immunity in

Dengue

11.00-12.00 Symposium 16: Dengue Case Management: Points

of Clinicians' Concern

Chair: John P Grieco (USA)

Co-chair: Theeraphap Chareonviriyaphap (THA)

Chair: Kenneth Rock (USA)

Co-chair: Stefan Fernandez (USA)

Chair: Suchitra Nimmannitya (THA)

Co-chair: Sri Rezeki H. Hadinegoro (IDN)

11.00-11.20 Tom Scott (USA)

The interplay between Aedes aegypti ecology and dengue

epidemiology

11.00-11.30 Richard J Kuhn (USA)

Dengue virus structure and dynamics

11.00-11.15 (0130R01) Raphael Zellweger (USA)

Cellular immunity mediates short-term protection against heterologous

dengue re-infection

11.00-11.20 Siripen Kalayanarooj (THA)

Dengue classifications and guidelines of clinical management: original

WHO vs. TDR 2009

11.20-11.40 John P Grieco (USA)

Aedes aegypti behavior : Potential impact on control interventions

11.15-11.30 (0157R01) Daniela Weiskopf (USA)

Comprehensive analysis of dengue-virus specific responses supports

an HLA-linked protective role for CD8+ T cells

11.20-11.40 LakKumar Fernando (LKA)

Guidelines and Beyond: How to deal with some difficult situations

11.40-12.00 Sylvie Manguin (FRA)

Global invasion and biology of the Aedes mosquito and associated

risk of dengue expansion

11.30-12.00 Ralf Bartenschlager (DEU)

New insights into the dengue virus replication cycle

11.30-11.45 (0069R01) Wilawan Chan-in (THA)

Anergy of human invariant natural killer T cells from acute dengue

virus infected patients

11.40-12.00 Tahira Cheema (PAK)

Facing 2011 Lahore dengue epidemic

11.45-12.00 (0275R01) Ruklanthi de Alwis (USA)

Characterization of DENV1 type-specific immunity using a strongly

neutralizing human monoclonal antibody

12.00-13.00

13.00-13.30


Poster Presentation

09.15-10.30

11.00-12.00


08.30-09.10

Break

Page 2 of 5


Day 1: 21 October 2013State-of-the-Art Lecture 3: 13.30-15.30 Symposium 17: Biology of Dengue Virus and

Dengue Virus-Host Interaction

13.30-15.35 Symposium 18: Integrated Vector Management (IVM)

Chair: Richard J Kuhn (USA)

Co-chair: Ralf Bartenschlager (DEU)

Chair: Raman Velayudhan (WHO/GENEVA)

Co-chair: A P Dash (WHO/SEARO)

13.30-14.00 Gavin Screaton (GBR)

Overview on pathogenesis of dengue virus infection

13.30-14.00 Rushika Perera (USA)

Alterations in cellular metabolism are keys to dengue virus replication

13.30-13.55 Raman Velayudhan (WHO/GENEVA) Global strategy

on integrated vector management

14.00-15.30 Symposium 19: Vascular Biology of Viral

Hemorrhagic Fevers

14.00-15.30 Symposium 17: (continued) 13.55-15.30 Symposium 18: (continued) 14.00-15.30 Symposium 20: Hematologic Changes in Dengue

Illness

Chair: Gavin Screaton (GBR)

Co-chair: Umesh Chaturvedi (IND)

13.55-14.20 A P Dash (WHO/SEARO)

IVM strategy for dengue prevention and control in WHO South East

Asian countries

Chair: Tanomsri Srichaikul (THA)

Co-chair: LakKumar Fernando (LKA)

14.00-14.25 Hans Schnittler (DEU)

Dynamics of endothelial junctions

14.00-14.15 (0028R01) Supranee Phanthanawiboon (JPN)

The NS3/NS4B region of dengue virus type 4 laboratory strain is a

determinant for efficient replication

14.00-14.30 Suchitra Nimmannitya (THA)

DHF-a unique viral hemorrhagic fever with pathophysiologic hallmarks

of plasma leakage and hematologic derangement

14.25-14.50 Christina Spiropoulou (USA)

Disruption of the endothelial cell barrier by Hantavirus infection

14.15-14.30 (0219R01) Kenneth Hodge (THA)

Exploration of the dengue RDRP-RNA interface essential for viral

replication

14.20-14.45 Raman Velayudhan (WHO/GENEVA)

WHOPES support judiceous use of insecticides according to IVM

strategy

14.30-14.45 (0242R01) Andrea Da Poian (BRA)

Alterations in hepatic lipid metabolism during dengue virus infection

14.30-15.00 Ampaiwan Chuansumrit (THA)

Hematologic derangement in DHF and management on massive

bleeding

14.50-15.15 Anon Srikiatkhachorn (THA)

Interactions between virus, immunity, and endothelium in dengue

14.45-15.00 (0140R01) Andrew Davidson (GBR)

High throughput quantitative proteomic analysis of dengue virus- host

cell interactions

14.45-15.10 Christina Liew (SGP)

Integrated vector management for dengue control in Singapore

15.00-15.15 (0284R01) Pornapat Surasombatpattana (FRA)

Role of saliva in dengue transmission 15.10-15.35 Boonserm Aumaung (THA) : Implementation of IVM

strategy for dengue prevention and control in Thailand

15.00-15.30 Tanomsri Srichaikul (THA)

Bone marrow involvement and hemophagocytic syndrome in dengue

15.30-16.00

16.00-17.35 Symposium 21: Pathogenesis 16.00-17.30 Symposium 22: Vector and Vector Control 16.00-17.30 Symposium 23: Next Generation Dengue Vaccines 16.00-19.00 Round Table Discussion on The Two

Classifications: DF/DHF/DSS VS. Mild/Severe Dengue

Chair: Guey-Chuen Perng (TWN)

Co-chair: Umesh Chaturvedi (IND)

Chair: Micheal Bangs (USA)

Co-chair: Chitapa Ketavan (THA)

Chair: Lance Gordon (USA)

Co-chair: Kristen M Bauer (USA)

Chair: Scott B Halstead (USA)

Co-chair: Pratap Singhasivanont (THA)

16.00-16.20 Guey-Chuen Perng (TWN)

Bone marrow stem/ progenitor cells in dengue pathogenesis

16.00-16.15 (0123R01) Ahbi Rami Rattanam (MYS)

Evaluation of biological activity of Ipomoea Cairica (Linn.) extract

against dengue vectors


Walter Reed Army Institute of Research Dengue Vaccine

Development Efforts

Suchitra Nimmannitya (THA) and Hasitha Tissera (LKA)

16.20-16.50 Prida Malasit (THA) and Khin Saw Aye (MMR)

Immuno-Histopathology studies of 13 autopsy cases of patients died

of dengue hemorrhagic fever

16.15-16.30 (0137R01) Emmanuel Elanga Ndille (BEN)

Human antibody response to Aedes aegypti salivary peptide as a

new indicator for assessing the risk of arboviruses transmission and

the efficacy of vector control, in dengue and chikungunya

transmission areas

Siripen Kalayanarooj (THA) and LakKumar Fernando (LKA)

Anon Srikiatkhachorn (THA)

16.30-16.45 (0045R01) Natapong Jupatanakul (USA)

Laboratory adaptation leads to global transcriptomic down -regulation

and dengue vector capacity changes in Aedes aegypti

16.30-17.00 Nopporn Sittisombut (THA)

Generation and immunogenicity testings of insect cell-derived dengue

virus-like particles

Tran Tinh Hien (VNM)

16.50-17.05 (0240R01) Eugenia Ong (SGP)

SYK-ING pathways for antibody-enhanced dengue virus infection

16.45-17.00 (0112R01) George Dimopoulos (USA)

The Aedes aegypti microbiome and its potential for dengue control

17.05-17.20 (0391R01) Ashutson Biswas (IND)

Pathogenesis of severity in DF/DHF/DSS: A case control study

17.00-17.15 (0112R02) George Dimopoulos (USA)

Targeting conserved human and mosquito host factors with drugs for

dengue control

17.00-17.30 Janine R Danko (USA)

A Phase I clinical trial of tetravalent dengue DNA vaccine with

Vaxfectin

17.20-17.35 (0129R01) Henry Stephens (GBR)

HLA CLASS I supertype profiles in Thai dengue patients

17.15-17.30 (0110R01) Christine Joyce Hernandez (PHL)

Community dengue "HOTSPOT" in The Philippines: a strategic area

for vector control

13.00-14.00

14.00-15.30

16.00-19.00

Break

Page 3 of 5



State-of-the-Art lecture 4: 8.30-9.30 Symposium 24: Clinical and Laboratory Diagnosis

Chair: Usa Thisyakorn (THA)

Co-chair: Sri Rezeki H. Hadinegoro (IDN)

08.30-09.00 John Aaskov (AUS)

How does dengue evolution tell us about a successful dengue

vaccine strategy?

08.30-08.45 (0211R01) Kalamathy Murugananthan (LKA)

Virological and immunological profiles in dengue fever suspected

patients from the northern province of Sri Lanka

09.00-10.30 Symposium 25: Vector and Vector Control

08.45-09.00 (0073R01) Pugpen Sirikutt (THA)

Serum lactate and lactate dehydrogenase (LDH), Parameters for

prediction of dengue severity

Chair: Nicole Achee (USA)

Co-chair: Alongkot Ponlawat (THA)

09.00-09.30 Joachim Hombach (WHO/GENEVA)

Global perspective on dengue vaccine development and introduction

09.00-09.15 (0371R01) Peter Ryan (AUS)

Using Wolbachia infections to control dengue transmission


Evaluation of the performance available dengue diagnostic tests for

the development of an optimal diagnostic algorithm from a single

specimen


Comparison of dengue virus vector competence of Aedes

mediovittatus, the Caribbean treehole mosquito, and Aedes aegypti

09.15-09.30 (0147R01) Kay Tomashek (PRI)

Dengue virus incubation periods: variability by temperature and

serotype

09.30-10.30 Symposium 26: Dengue Vaccine Under Clinical

Trials I

09.30-10.30 Symposium 27: Tools for Vaccine Trial 09.30-10.30 Symposium 25: (Continued) 09.30-10.30 Symposium 28: Dengue Virus Evolution and

Epidemiology

Chair: Joachim Homach (WHO/GENEVA)

Co-chair: Arunee Sabchareon (THA)

Chair: Umesh Chaturvedi (IND)

Co-chair: Nopporn Sittisombut (THA)

Chair: Duncan R Smith (GBR)

Co-chair: Richard G Jarman (USA)

09.30-09.50 Charung Muangchana (THA)

Use of the first dengue vaccine in Thailand

09.30-09.50 Sujan Shresta (USA)

The Role of cellular and humoral immunity in dengue vaccination

09.30-09.45 (0226R01) Gerhart Knerer (GBR)

Impact of combined vector-control and vaccination straqtegies on

transmission dynamics of dengue fever in Thailand - a modelling study

09.30-09.50 Richard G Jarman (USA)

Evolution of dengue viruses in defined geographical space in Thailand

09.50-10.10 Melanie Saville (FRA)

Update on Sanofi Pasteur dengue vaccine development

09.50-10.05 (0096R01) Takeshi Kurosu (JPN)

Animal model for dengue virus infection and evaluation of therapeutics

09.45-10.00 (0271R01) Dawn M Wesson (USA)

Validation of an attractive lethal ovitrap (ALOT) for dengue control in

Iquitos, Peru09.50-10.05 (0039R01) Malayvanh Lao (LAO)

Detection and typing of dengue strains in Vientiane capital, LAO PDR

10.10-10.30 Arunee Sabchareon (THA)

Understanding the first dengue vaccine efficacy trial

10.05-10.20 (0248R01) Kuan Rong Chan (SGP)

The involvement of FCGAMMARIIB in dengue virus neutralization

10.00-10.15 (0181R01) Wasana Boonyuan (THA)

Excito - repellency of thai essential oils against Aedes aegypti (L.)

field population in Thailand

10.05-10.20 (0255R01) Eng Eong Ooi (SGP)

Viral determinants of epidemic dengue

10.15-10.30 (0183R01) Sunaiyana Sathantriphop (THA)

Charaterization of four plant essential oils against Aedes aegypti

10.30-11.00

11.00-12.00 Symposium 29: Dengue Vaccine Under Clinical

Trials II

11.00-12.00 Symposium 30: Clinical aspects and treatments 11.00-12.00 Symposium 31: Anti-Dengue Virus Agents 11.00-12.00 Symposium 32: DENV Evolution and Vaccine

Chair: Harold Margolis (USA)

Co-chair: Chukiat Sirivichayakul (THA)

Chair: Siripen Kalayanarooj (THA)

Co-chair: Tahira Cheema (PAK)

Chair: Sukathida Ubol (THA)

Co-chair: Wei-Kung Wang (USA)

Chair: John Aaskov (AUS)

Co-chair: Timothy Endy (USA)

11.00-11.20 Stephen S Whitehead (USA)

NIAID LID/Butantan: Dengue vaccine ph 1, 2

11.00-11.15 (0148R01) Esther Ellis (PRI)

Dengue - associated hemophagocytic lymphohistiocytosis in Puerto

Rico

11.00-11.20 Wei-Kung Wang (USA)

Stem region of dengue virus envelope protein as potential target of

antiviral strategy

11.00-11.15 (0210R01) Thanh Le Viet (VNM)

The emergence of dengue in Hanoi, Vietnam: preliminary results of

serotype surveillance in 2011, 2012

11.20-11.40 Gilad Gordon (USA)

Inviragen DENVax ph 2 "Safety and immunogenicity of DENVax in

diverse age groups and populations"

11.15-11.30 (0325R01) Victor Gan (SGP)

Utility of warning signs in predicting severe dengue and guiding

admission

11.20-11.35 (0009R02) Kazuyoshi Ikuta (JPN)

Human monoclonal antiboies derived from dengue patients mostly

recognize dengue virus envelope domain II with different effects for

the reactivities with this epitope region with substitutions at different

amino acid residues

11.15-11.30 (0264R01) October Sessions (SGP)

Selective pressure from two hosts enforces genetic stability of

dengue virus

11.40-12.00 Jorge Osorio (USA)

Dissecting the immune response to a chimeric dengue vaccine

11.30-11.45 (0266R01) Ananda Wijewickrama (LKA)

Hepatic involvement in adult dengue patients11.35-11.50 (0341R01) Andrew Sayce (GBR)

N-Methoxynonyl-Deoxynojirimycin modulates the innate immune

response to dengue virus: clinical implications

11.30-11.45 (0164R01) Shuzhen Sim (SGP)

Tracking dengue virus intrahost genetic diversity during human-to-

mosquito transmission

11.45-12.00 (0068R01) Steven Moulton (USA)

Noninvasive method for fluid resuscitation monitoring in dengue

hemorrhagic fever: a preliminary report

11.50-12.05 (0224R01) Nuno Santos (PRT)

Dengue virus capsid protein binding to lipid droplets and its inhibition.

Towards a new drug target

11.45-12.00 (0354R01) Luis Mier-y-Teran-Romero (USA)

Vaccine facilitated re-introduction of displaced dengue serotypes

12.00-13.00

13.00-14.00

09.30-10.30

Break

08.30-09.30

11.00-12.05


Poster Presentation


Page 4 of 5


Day 1: 21 October 201314.00-14.40 FUNDING and RESEARCH OPPORTUNITIES in DENGUE

14.00-14.20 Cristina Cassetti (NIH) : NIAID Dengue Research Program and Funding Opportunities

14.20-14.40 Georges Thiry (DVI) : DVI's perspective on dengue

15.45-16.00 CLOSING SPEECH: Professor Emeritus Prasert Thongcharoen

14.00-15.45

14.40-15.45 PANEL DISCUSSION

1. Duane Gubler (USA)

2. Raman Velayudhan (WHO/GENEVA)

3. Pratap Singhasivanont (THA)

4. Prida Malasit (THA)

Dr. Supamit Chunsuttiwat (Modulator)

Page 5 of 5

Documents

3rd International Conference on Dengue and DHF Schedule-15 Sep 13-Approved.pdf